› Forums › General Melanoma Community › Novartis–LEE011
- This topic has 24 replies, 3 voices, and was last updated 11 years, 1 month ago by
POW.
- Post
- Replies
-
-
- December 6, 2013 at 11:36 pm
The LEE011 Phase 1 clinical trials are brand new– just announced within the last month or so– so not very many of the folks here have experience with it yet.
Apparently, LEE011 is a small molecule similar to MEK in some respects. Although researchers hope that it will kill breast cancer, melanoma, and some other cancers, what they really expect is that it will perform especially well in combination with other small molecule targeted treatments like the BRAF inhibitors by preventing the cancer cells from becoming resistant to the targeted therapies.
This is all pie-in-the-sky right now, but a series of Phase 1 trials of LEE011 alone and in combination have begun. Let's keep our fingers crossed! Please keep us posted about how things go for you.
-
- December 6, 2013 at 11:36 pm
The LEE011 Phase 1 clinical trials are brand new– just announced within the last month or so– so not very many of the folks here have experience with it yet.
Apparently, LEE011 is a small molecule similar to MEK in some respects. Although researchers hope that it will kill breast cancer, melanoma, and some other cancers, what they really expect is that it will perform especially well in combination with other small molecule targeted treatments like the BRAF inhibitors by preventing the cancer cells from becoming resistant to the targeted therapies.
This is all pie-in-the-sky right now, but a series of Phase 1 trials of LEE011 alone and in combination have begun. Let's keep our fingers crossed! Please keep us posted about how things go for you.
-
- December 6, 2013 at 11:36 pm
The LEE011 Phase 1 clinical trials are brand new– just announced within the last month or so– so not very many of the folks here have experience with it yet.
Apparently, LEE011 is a small molecule similar to MEK in some respects. Although researchers hope that it will kill breast cancer, melanoma, and some other cancers, what they really expect is that it will perform especially well in combination with other small molecule targeted treatments like the BRAF inhibitors by preventing the cancer cells from becoming resistant to the targeted therapies.
This is all pie-in-the-sky right now, but a series of Phase 1 trials of LEE011 alone and in combination have begun. Let's keep our fingers crossed! Please keep us posted about how things go for you.
-
- March 24, 2014 at 8:20 pm
Oh, shoot! I'm sorry for your disappointment. But thank you so much for volunteering to help test out this new drug. Without people like you, melanoma research would be dead in the water.
I assume that you know that Merck's anti-PD1 (MK-3475) is just becoming available for expanded access? Could that be an option for you? Or perhaps an antibody-drug conjugate (ADC) trial?
-
- March 24, 2014 at 8:20 pm
Oh, shoot! I'm sorry for your disappointment. But thank you so much for volunteering to help test out this new drug. Without people like you, melanoma research would be dead in the water.
I assume that you know that Merck's anti-PD1 (MK-3475) is just becoming available for expanded access? Could that be an option for you? Or perhaps an antibody-drug conjugate (ADC) trial?
-
- March 24, 2014 at 8:20 pm
Oh, shoot! I'm sorry for your disappointment. But thank you so much for volunteering to help test out this new drug. Without people like you, melanoma research would be dead in the water.
I assume that you know that Merck's anti-PD1 (MK-3475) is just becoming available for expanded access? Could that be an option for you? Or perhaps an antibody-drug conjugate (ADC) trial?
-
- You must be logged in to reply to this topic.